A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Sponsor: |
Merck |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAO8259 |
U.S. Govt. ID: |
NCT02335411 |
Contact: |
Gulam Manji, MD: 646-317-6085 / gam2140@cumc.columbia.edu |
The purpose of this study is to assess the safety, tolerablility, and effectiveness of pembrolizumab alone or in combination with standard treatment (cisplatin and 5-fluorouracil) for recurrent or metastatic Gastric Cancer or Gastroesophageal Junction Cancer. Participants will be in the study for approximately 24 months.
This study is closed
Investigator
Gulam Manji, MD, PhD
Do you suffer from gastric or gastroesophageal junction cancer? |
Yes |
No |